Dermatology

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

A new analysis found a 0.78% prevalence of CSU in US adults, exceeding earlier estimates, and revealed significant mental, physical, and work-related burdens.

FDA approves delgocitinib cream, offering a new treatment option for adults with moderate-to-severe chronic hand eczema.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

In this interview segment, Hamade highlights the potential benefits of an oral drug like deucravacitinib in psoriasis and psoriatic arthritis.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.

This analysis highlights differences between topical and oral finasteride for hair loss, specifically looking at adverse events and any causal connections.

This July 15, 2025 SOCS News Update highlights Regine Mathieu, MD's experiences and views on collaboration opportunities.

Alopecia significantly impacts life quality, with stigma and negative perceptions contributing to mental health issues such as anxiety and depression.

This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fourth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.